For tablet manufacture, Lotion Veterinary Grade API is pre-screened through a 30-mesh stainless steel sieve before formulation assessment. Direct compression is selected only when bulk density falls between 0.35 g/mL and 0.65 g/mL, Carr’s index remains below 25%, and particle size distribution shows D90 between 75 µm and 150 µm. When these thresholds are not met, wet granulation with povidone K30 (Ph. Eur. 1303) at 2–4% w/w is substituted. In a 300 L Fielder PMA high-shear granulator, the dry blend is pre-mixed for 3 min at impeller 150 rpm, then granulated with purified water added at 8–12% w/w at impeller 300 rpm and chopper 1,500 rpm for 4–6 min. The wet mass is dried in a Glatt GPCG 60 fluid bed at inlet 60–65°C until product temperature reaches 35–40°C and loss on drying is 1.5–2.5%. Compression is performed on a Kilian T200 rotary press with B-tooling at 10–15 kN and 60,000 tablets/h. A representative wet granulation formula is API 5–30% w/w, microcrystalline cellulose 20–40% w/w, lactose monohydrate 20–40% w/w, croscarmellose sodium 2–5% w/w, povidone K30 2–4% w/w, colloidal silicon dioxide 0.5–1.0% w/w, and magnesium stearate 0.5–1.0% w/w. Finished tablets are tested for hardness (70–100 N), friability (≤0.8% per USP <1216>), disintegration (≤15 min in 0.1 N HCl per USP <701>), and uniformity of dosage units per USP <905> or Ph. Eur. 2.9.5. The terminal product is a light-protective aluminium-aluminium blister or white HDPE bottle with desiccant.

Thermal Sterilization Is Not Always Feasible for Heat-Labile Injectable APIs

Veterinary parenteral applications of Lotion Veterinary Grade API require a sterile bulk solution prepared in Water for Injection (Ph. Eur. 0169) with a fill volume of 102% of label claim. Preformulation solubility is measured at 20–25°C in media from pH 4.5 to 7.0; if equilibrium solubility is below 5 mg/mL, co-solvent systems containing propylene glycol 10–30% v/v or glycofurol 10–20% v/v are screened. Terminal sterilization at 121°C for 15 min is considered only after ICH Q1A(R2)-style forced degradation confirms assay loss below 2% and total impurities below 1.0%. Heat-labile preparations are filtered through a 0.22 µm PVDF membrane and aseptically filled in Grade A laminar airflow. Benzyl alcohol at 1.0–1.5% v/v is included only in multi-dose vials where species-specific tolerance data exist. Nitrogen overlay to dissolved oxygen below 0.5 mg/L is applied when oxidative degradation appears in forced degradation. For suspension injections, wet milling to D90 ≤10 µm and viscosity between 20 mPa·s and 100 mPa·s are targeted for syringability. Finished vials are tested for sterility per USP <71>, bacterial endotoxins per USP <85> at ≤0.5 EU/mg, subvisible particulate matter per USP <787>, and pH outside the degradation-sensitive range. Published data for the aqueous degradation kinetics of Lotion Veterinary Grade API are limited; the pH-rate profile and activation energy must be determined before the terminal sterilization cycle is fixed. The terminal product is a 50 mL or 100 mL amber borosilicate vial sealed with bromobutyl rubber stoppers and aluminium flip-off caps.

What Limits Uniformity in Low-Dose Veterinary Capsules?

Hard gelatin capsule filling with Lotion Veterinary Grade API at mass fractions below 5% w/w is limited by powder segregation and electrostatic adhesion. The API is micronized to D90 ≤20 µm by nitrogen jet milling, then introduced by geometric dilution in a 100 L bin blender. The first 1:10 API-to-lactose monohydrate pre-blend is mixed for 10 min at 20 rpm, screened through a 0.5 mm stainless steel mesh, and diluted. Final blend composition is API 2–20% w/w, lactose monohydrate 60–80% w/w, pregelatinized starch 10–20% w/w, sodium starch glycolate 2–5% w/w, and magnesium stearate 0.5% w/w. Encapsulation is run on a Bosch GKF 705 tamping pin filler at 30,000–60,000 capsules/h with a target fill weight of 150–350 mg. Weight variation is controlled to ±5%, and content uniformity is assessed per USP <905> with acceptance value ≤15.0. Dissolution is determined using USP <711> apparatus 2 at 50 rpm in 900 mL of deaerated 0.1 N HCl at 37°C; the Q value is set from preformulation solubility data. If the API contains primary amine groups or the gelatin source is not certified low-aldehyde, cross-linking risk is evaluated by storing filled capsules at 40°C/75% RH for 4 weeks and re-testing dissolution. The terminal capsule product is packaged in PVC/PVDC/aluminium blisters with a moisture barrier.

When Oral Powders Are Metered Through Drinking Water Systems

Drinking-water-soluble powders for poultry and swine require Lotion Veterinary Grade API to remain in solution at doses from 0.05 g/L to 1.0 g/L in water with hardness up to 250 ppm CaCO₃ for 24 h. The carrier matrix is formulated with API 10–50% w/w, dextrose monohydrate 40–70% w/w, anhydrous citric acid 0.5–1.5% w/w, trisodium citrate dihydrate 0.5–2.0% w/w, and colloidal silicon dioxide 0.2–0.5% w/w. Mixing is performed in a 300 kg ribbon mixer at 20 rpm for 15 min; bulk density is held at 0.55–0.75 g/mL to reduce segregation during sachet filling. Fill weight tolerance for 100 g, 500 g, and 1 kg sachets is ±3%. The sachet laminate is PET/aluminium/LLDPE foil with oxygen transmission rate below 0.1 cm³/m²/day. Loss on drying is tested per Ph. Eur. 2.2.32 and maintained below 3.0%. Reconstitution behavior is checked in 1 L of 250 ppm hard water at 20°C: no visible precipitation after 24 h, pH between 6.0 and 7.0, and assay retention 95–105% of label claim. The terminal powder is a single-dose sachet or multi-dose HDPE jar with a scoop; desiccant is included when the API is hygroscopic.

Granulated intermediates for oral top-dressing of swine and cattle are produced when Lotion Veterinary Grade API shows poor flow or dusting potential. The granulation fluid is purified water containing 3–5% w/w povidone K30; dry solids are composed of API 10–40% w/w, microcrystalline cellulose 30–50% w/w, lactose monohydrate 15–30% w/w, and crospovidone 2–4% w/w. Extrusion is carried out on a Nica E140 screw extruder with 0.8–1.2 mm dome screens at 25 rpm, followed by spheronization on a Caleva 380 at 700 rpm for 3–5 min. Spheronized pellets are dried in a Glatt fluid bed at inlet 60°C until loss on drying is ≤2.0% per Ph. Eur. 2.2.32. The dried granulate is sieved to retain 0.5–1.4 mm; fines below 0.5 mm are re-granulated or discarded to avoid dust. Content uniformity is measured by sampling 10 unit doses and applying Ph. Eur. 2.9.5; water activity is controlled to ≤0.60 via USP <1112> to limit microbial growth. The terminal product is filled into white HDPE jars with induction-sealed caps and a molecular sieve desiccant. If the API is thermolabile, drying temperature is reduced to 40–45°C with extended cycle time, but loss on drying must still reach ≤2.0% to avoid granule hardening.

Medicated Premix Homogeneity in 1,000 kg Ribbon Mixers

Medicated premix production uses Lotion Veterinary Grade API as a concentrated intermediate for feed mill repartition. The active fraction is 0.5–5.0% w/w; the carrier is ground limestone (calcium carbonate, Ph. Eur. 0176) or washed corn cob granules with particle size between 200 µm and 800 µm. Mineral oil at 0.5% w/w is sprayed onto the carrier before API addition to reduce dust and electrostatic separation. A 1,000 kg horizontal ribbon mixer is charged first with 20% of the carrier, then the API pre-blend, then the remaining carrier; mixing continues for 10 min at tip speed 1.2 m/s. After discharge, 10 sampling points are assayed; the coefficient of variation must be ≤5.0%, and release assay must fall within 95–105% of label claim. Carry-over is limited by flushing the mixer with 50 kg ground limestone after every batch; the following batch must show carry-over below 0.5% of the previous API concentration. Compliance is governed by FDA 21 CFR 225 (cGMP for medicated feeds) and Regulation (EU) 2019/4. The finished premix is packaged in 25 kg multi-wall paper bags with an inner polyethylene liner; moisture content is held below 3% to prevent caking and assay drift.

Solutions for drinking water administration impose a narrower stability window than dry powder forms. Lotion Veterinary Grade API is dissolved in purified water with 10 mM phosphate buffer to maintain pH between 6.0 and 7.0; the product is filled into 1 L or 5 L white HDPE bottles with a fill volume tolerance of ±2%. Chemical stability is tested at 25°C/60% RH and 40°C/75% RH for 6 months; an assay loss above 5% or total impurities above 2.0% at the accelerated condition triggers pH modification, antioxidant addition, or packaging change. Preservative efficacy for multi-dose containers is confirmed according to USP <51> or Ph. Eur. 5.1.3. Visible particles and photostability are monitored per VICH GL3; amber over-pack is used when light exposure produces impurity growth. Published data for the specific solution stability of Lotion Veterinary Grade API are limited; the above limits are initial acceptance criteria that must be confirmed by forced degradation. If the API has limited aqueous solubility, a concentrated solution route is rejected in favor of the oral powder or granulate form unless a co-solvent system is compatibility-tested in the field. The terminal product is a capped HDPE bottle with tamper-evident seal and a dosing pump for water proportioner lines.